Follicular Lymphoma
Conference Coverage
CARs race for supremacy against aggressive non-Hodgkin lymphoma
MADRID - Two chimeric antigen receptor T cell (CAR-T) constructs are showing promising activity against treatment-refractory, aggressive forms of...
News
New SC rituximab formulation approved, reduces administration time
The US Food and Drug Administration (FDA) approved a new, subcutaneous (SC) formulation of rituximab with hyaluronidase human (Rituxan Hycela™)....
Conference Coverage
Twofer drug blocks SYK/JAK pathways in advanced NHL
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK)...
Conference Coverage
Chemo-free triplet produces ‘favorable’ results in advanced disease
LUGANO, SWITZERLAND—A chemotherapy-free combination regimen has demonstrated “favorable” safety and efficacy in patients with advanced chronic...
News
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Conference Coverage
Inhibitor elicits responses in heavily pretreated FL, DLBCL
LUGANO, SWITZERLAND—Interim results of a phase 2 trial suggest tazemetostat can be effective in patients with heavily pretreated, relapsed or...
Conference Coverage
Lenalidomide-rituximab induces high CR rate in untreated follicular lymphoma
LUGANO, SWITZERLAND – The combination “can be a highly effective and reasonably well-tolerated treatment approach for patients with untreated...
Conference Coverage
GALEN safe and effective in relapsed and refractory follicular lymphoma
LUGANO, SWITZERLAND – Obinutuzumab, a follow-on to rituximab, appeared to be especially useful in combination with lenalidomide among patients who...
News
Biosimilar rituximab approved in Europe
The European Commission (EC) has approved the Sandoz biosimilar rituximab (Rixathon®) for use in the European Economic Area. Rixathon is approved...
News
BLA for CAR T-cell therapy granted priority review
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for axicabtagene ciloleucel (...
News
FDA grants priority review to NDA for copanlisib
The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for copanlisib, an intravenous PI3K...